{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:02:28Z","timestamp":1789243348038,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"technology Development Fund of Nanjing Medical University","award":["NMUB2020069"],"award-info":[{"award-number":["NMUB2020069"]}]},{"name":"Major Research plan of Changzhou Health Commission of Jiangsu Province of China","award":["ZD202215"],"award-info":[{"award-number":["ZD202215"]}]},{"name":"the Changzhou Sci&Tech Program","award":["CE20225051"],"award-info":[{"award-number":["CE20225051"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270328"],"award-info":[{"award-number":["82270328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"crossref","award":["BK20221229"],"award-info":[{"award-number":["BK20221229"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Sodium-glucose cotransporter 2 (SGLT2) inhibitors have well-documented effects in reducing hospitalization or cardiovascular mortality, while the association of SGLT2 inhibitor dapagliflozin (DAPA) and the risk of acute kidney injury (AKI) in acute myocardial infarction (AMI) patients has not been comprehensively investigated. Therefore, we aimed to assess the association between DAPA and AKI risk in AMI patients after percutaneous coronary intervention (PCI) therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the Changzhou Acute Myocardial Infarction Registry database, we retrospectively included AMI patients from January 2017 to August 2021 and analyzed the risk of AKI and all-cause mortality after PCI therapy. The patients were divided into two groups according to the use of DAPA (DAPA group and Ctrl group). Patients in the DAPA group started to use DAPA after admission and continued its use during hospitalization and follow-up period. Baseline characteristics were balanced between the two groups with a propensity score matching (PSM) analysis. The outcome was AKI within 7\u00a0days after PCI and all-cause mortality during a follow-up of 2\u00a0years. Univariate and multivariate logistic regression analyses were used to assess the association between DAPA and AKI risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 1839 AMI patients undergoing PCI were enrolled. DAPA was used in 278 (15.1%) patients. Postoperative AKI occurred in 351 (19.1%) cases. A 1:1 PSM analysis was used to reduce confounding factors. The multivariate stepwise regression analysis showed that DAPA (odds ratio, OR 0.66; 95% confidence interval, CI 0.44\u20130.97; <jats:italic>P<\/jats:italic>\u2009=\u20090.036) was an independent protective factor in the entire cohort. After matching, the use of DAPA in AMI patients was independently associated with a decline of AKI risk (OR 0.32; 95% CI, 0.19\u20130.53; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) after hospital admission. Meanwhile, there were significant differences in mortality between the DAPA group and Ctrl group (2.5% vs. 7.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.012).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>SGLT2 inhibitor DAPA was associated with lower risks of incident AKI and all-cause mortality in AMI patients after PCI therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-024-03623-7","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T11:04:31Z","timestamp":1707217471000},"page":"613-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients"],"prefix":"10.1007","volume":"80","author":[{"given":"Dabei","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lipeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"12","key":"3623_CR1","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"EJ Benjamin","year":"2018","unstructured":"Benjamin EJ, Virani SS, Callaway CW et al (2018) Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation 137(12):e67\u2013e492","journal-title":"Circulation"},{"issue":"9351","key":"3623_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0140-6736(03)12113-7","volume":"361","author":"EC Keeley","year":"2003","unstructured":"Keeley EC, Boura JA, Grines CL (2003) Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361(9351):13\u201320","journal-title":"Lancet"},{"key":"3623_CR3","doi-asserted-by":"crossref","unstructured":"Hochman JS, Sleeper LA, Webb JG et al (1999) Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 341(9):625\u201334","DOI":"10.1056\/NEJM199908263410901"},{"issue":"10315","key":"3623_CR4","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/S0140-6736(21)02326-6","volume":"398","author":"R Mehran","year":"2021","unstructured":"Mehran R, Owen R, Chiarito M et al (2021) A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. Lancet 398(10315):1974\u20131983","journal-title":"Lancet"},{"issue":"4","key":"3623_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1161\/CIRCULATIONAHA.110.970160","volume":"123","author":"MT James","year":"2011","unstructured":"James MT, Ghali WA, Knudtson ML et al (2011) Associations between acute kidney injury and cardiovascular and renal outcomes after coronary angiography. Circulation 123(4):409\u2013416","journal-title":"Circulation"},{"issue":"10212","key":"3623_CR6","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","volume":"394","author":"C Ronco","year":"2019","unstructured":"Ronco C, Bellomo R, Kellum JA (2019) Acute kidney injury. Lancet 394(10212):1949\u20131964","journal-title":"Lancet"},{"issue":"6","key":"3623_CR7","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1053\/j.ajkd.2008.11.034","volume":"53","author":"SG Coca","year":"2009","unstructured":"Coca SG, Yusuf B, Shlipak MG et al (2009) Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 53(6):961\u2013973","journal-title":"Am J Kidney Dis"},{"issue":"9","key":"3623_CR8","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.amjcard.2013.06.008","volume":"112","author":"S Khera","year":"2013","unstructured":"Khera S, Kolte D, Aronow WS et al (2013) Trends in acute kidney injury and outcomes after early percutaneous coronary intervention in patients \u226575 years of age with acute myocardial infarction. Am J Cardiol 112(9):1279\u20131286","journal-title":"Am J Cardiol"},{"issue":"15","key":"3623_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383(15):1413\u20131424","journal-title":"N Engl J Med"},{"issue":"4","key":"3623_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357","journal-title":"N Engl J Med"},{"issue":"11","key":"3623_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s41569-020-00455-7","volume":"17","author":"GB Lim","year":"2020","unstructured":"Lim GB (2020) Empagliflozin improves outcomes in HFrEF regardless of diabetic status. Nat Rev Cardiol 17(11):681","journal-title":"Nat Rev Cardiol"},{"issue":"12","key":"3623_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.cardfail.2021.04.023","volume":"27","author":"H Tsutsui","year":"2021","unstructured":"Tsutsui H, Ide T, Ito H et al (2021) JCS\/JHFS 2021 Guideline focused update on diagnosis and treatment of acute and chronic heart failure. J Card Fail 27(12):1404\u20131444","journal-title":"J Card Fail"},{"issue":"1","key":"3623_CR13","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41598-020-64380-y","volume":"10","author":"A Kuno","year":"2020","unstructured":"Kuno A, Kimura Y, Mizuno M et al (2020) Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats. Sci Rep 10(1):7238","journal-title":"Sci Rep"},{"issue":"3","key":"3623_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","volume":"36","author":"JS Alpert","year":"2000","unstructured":"Alpert JS, Thygesen K, Antman E et al (2000) Myocardial infarction redefined\u2013a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36(3):959\u2013969","journal-title":"J Am Coll Cardiol"},{"key":"3623_CR15","doi-asserted-by":"crossref","unstructured":"Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461\u201370","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"issue":"Suppl 1","key":"3623_CR16","doi-asserted-by":"publisher","first-page":"S67","DOI":"10.2337\/dc13-S067","volume":"36","author":"American Diabetes Association","year":"2013","unstructured":"American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes Care 36(Suppl 1):S67\u2013S74","journal-title":"Diabetes Care"},{"key":"3623_CR17","unstructured":"Mcmurray JJ, Adamopoulos S, Anker SD et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787\u2013847"},{"issue":"1","key":"3623_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/cc11454","volume":"17","author":"JA Kellum","year":"2013","unstructured":"Kellum JA, Lameire N (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17(1):204","journal-title":"Crit Care"},{"key":"3623_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ijcard.2019.01.070","volume":"283","author":"G Chalikias","year":"2019","unstructured":"Chalikias G, Serif L, Kikas P et al (2019) Long-term impact of acute kidney injury on prognosis in patients with acute myocardial infarction. Int J Cardiol 283:48\u201354","journal-title":"Int J Cardiol"},{"issue":"11","key":"3623_CR20","first-page":"1693","volume":"67","author":"I Khan","year":"2017","unstructured":"Khan I, Dar MH, Khan A et al (2017) Frequency of acute kidney injury and its short-term effects after acute myocardial infarction. J Pak Med Assoc 67(11):1693\u20131697","journal-title":"J Pak Med Assoc"},{"issue":"8","key":"3623_CR21","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1177\/2048872617708975","volume":"7","author":"J Schmucker","year":"2018","unstructured":"Schmucker J, Fach A, Becker M et al (2018) Predictors of acute kidney injury in patients admitted with ST-elevation myocardial infarction-results from the Bremen STEMI-Registry. Eur Heart J Acute Cardiovasc Care 7(8):710\u2013722","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"14","key":"3623_CR22","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1097\/CM9.0000000000000293","volume":"132","author":"C Wang","year":"2019","unstructured":"Wang C, Pei YY, Ma YH et al (2019) Risk factors for acute kidney injury in patients with acute myocardial infarction. Chin Med J (Engl) 132(14):1660\u20131665","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"3623_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3109\/0886022X.2016.1148558","volume":"38","author":"YB Sun","year":"2016","unstructured":"Sun YB, Liu BC, Zou Y et al (2016) Risk factors of acute kidney injury after acute myocardial infarction. Ren Fail 38(9):1353\u20131358","journal-title":"Ren Fail"},{"issue":"6","key":"3623_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1097\/FJC.0000000000001268","volume":"79","author":"X Huang","year":"2022","unstructured":"Huang X, Guo X, Yan G et al (2022) Dapagliflozin attenuates contrast-induced acute kidney injury by regulating the HIF-1\u03b1\/HE4\/NF-\u03baB pathway. J Cardiovasc Pharmacol 79(6):904\u2013913","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"3623_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.7150\/ijms.69031","volume":"19","author":"PJ Chi","year":"2022","unstructured":"Chi PJ, Lee CJ, Hsieh YJ et al (2022) Dapagliflozin ameliorates lipopolysaccharide related acute kidney injury in mice with streptozotocin-induced diabetes mellitus. Int J Med Sci 19(4):729\u2013739","journal-title":"Int J Med Sci"},{"key":"3623_CR26","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1475-2840-13-28","volume":"13","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N et al (2014) The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 13:28","journal-title":"Cardiovasc Diabetol"},{"key":"3623_CR27","doi-asserted-by":"crossref","unstructured":"Kawanami D, Matoba K, Takeda Y et al (2017) SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci 18(5)","DOI":"10.3390\/ijms18051083"},{"issue":"6","key":"3623_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100777","volume":"9","author":"N Terami","year":"2014","unstructured":"Terami N, Ogawa D, Tachibana H et al (2014) Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice. PLoS ONE 9(6):e100777","journal-title":"PLoS ONE"},{"issue":"10","key":"3623_CR29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH et al (2016) Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 134(10):752\u2013772","journal-title":"Circulation"},{"issue":"5","key":"3623_CR30","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/ejhf.1432","volume":"21","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Demets DL, Inzucchi SE et al (2019) A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur J Heart Fail 21(5):665\u2013675","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"3623_CR31","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J et al (2021) Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial. Circulation 143(4):326\u2013336","journal-title":"Circulation"},{"issue":"6","key":"3623_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40256-022-00545-6","volume":"22","author":"YJ Wu","year":"2022","unstructured":"Wu YJ, Wang SB, Wang LS (2022) SGLT2 Inhibitors: new hope for the treatment of acute myocardial infarction?. Am J Cardiovasc Drugs 22(6):601\u2013613","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"3623_CR33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215\u2013225","journal-title":"Diabetologia"},{"key":"3623_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","volume":"66","author":"V Vallon","year":"2015","unstructured":"Vallon V (2015) The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med 66:255\u2013270","journal-title":"Annu Rev Med"},{"key":"3623_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","volume":"104","author":"TM Lee","year":"2017","unstructured":"Lee TM, Chang NC, Lin SZ (2017) Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med 104:298\u2013310","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"3623_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S et al (2019) SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic Heart. JACC Basic Transl Sci 4(1):15\u201326","journal-title":"JACC Basic Transl Sci"},{"issue":"1","key":"3623_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12933-017-0510-1","volume":"16","author":"C Ott","year":"2017","unstructured":"Ott C, Jumar A, Striepe K et al (2017) A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol 16(1):26","journal-title":"Cardiovasc Diabetol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-024-03623-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-024-03623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T08:35:32Z","timestamp":1710318932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-024-03623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["3623"],"URL":"https:\/\/doi.org\/10.1007\/s00228-024-03623-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"18 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Ethics Committee of the Affiliated Changzhou the Second People\u2019s Hospital of Nanjing Medical University, and carried out in accordance with the principles of the Declaration of Helsinki. The ethics approval number was 2020-KY253-01. The requirement for informed\u00a0consent forms for the patients was waived by our institution due to the retrospective nature of the\u00a0study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}